{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:37:58Z","timestamp":1762875478236},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,9,25]],"date-time":"2012-09-25T00:00:00Z","timestamp":1348531200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>To investigate a possible role of Cefditoren, a recently marketed in Greece third-generation oral cephalosporin in urinary infections of outpatients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>During a multicenter survey of Enterobacteriaceae causing UTIs in outpatients during 2005\u20132007, Cefditoren MICs were determined by agar dilution method in a randomly selected sample of uropathogens. Susceptibility against 18 other oral\/parenteral antimicrobials was determined according to Clinical and Laboratory Standards Institute methodology.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 563 isolates (330 <jats:italic>Escherichia coli<\/jats:italic>, 142 <jats:italic>Proteus mirabilis<\/jats:italic> and 91 <jats:italic>Klebsiella<\/jats:italic> spp) was studied; MIC50\/MIC90 of Cefditoren was 0.25\/0.5\u2009mg\/L respectively, with 97.1% of the isolates being inhibited at 1\u2009mg\/L. All 12 strains producing ESBLs or AmpC enzymes were resistant to cefditoren. Susceptibility rates (%) for amoxicillin\/clavulanic acid, cefuroxime axetil, cefotaxime, ciprofloxacin, trimethoprim\/sulfamethoxazole and fosfomycin were 93.1- 94.1- 96.8-93.1-71.9 and 92.8% respectively. Cefditoren MIC was significantly higher in nalidixic\/ciprofloxacin non-susceptible strains; resistance to cefditoren was not associated with resistance to mecillinam, fosfomycin nitrofurantoin and aminoglycosides. Multivariate analysis demonstrated history of urinary infection in the last two weeks or three months as risk factors for cefditoren resistance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Cefditoren exhibited enhanced in vitro activity against the most common uropathogens in the outpatient setting, representing an alternative oral treatment option in patients with risk factors for resistance to first-line antibiotics.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2334-12-228","type":"journal-article","created":{"date-parts":[[2012,9,25]],"date-time":"2012-09-25T20:38:10Z","timestamp":1348605490000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cefditoren: Comparative efficacy with other antimicrobials and risk factors for resistance in clinical isolates causing UTIs in outpatients"],"prefix":"10.1186","volume":"12","author":[{"given":"Despina","family":"Hatzaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garyphallia","family":"Poulakou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Katsarolis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niki","family":"Lambri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Souli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Deliolanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios K","family":"Nikolopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelia","family":"Lebessi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Giamarellou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,9,25]]},"reference":[{"issue":"Suppl 1A","key":"2090_CR1","doi-asserted-by":"publisher","first-page":"14S","DOI":"10.1016\/S0002-9343(02)01055-0","volume":"113","author":"A Ronald","year":"2002","unstructured":"Ronald A: The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med. 2002, 113 (Suppl 1A): 14S-19S.","journal-title":"Am J Med"},{"key":"2090_CR2","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.eururo.2008.05.010","volume":"54","author":"KG Naber","year":"2008","unstructured":"Naber KG, Schito G, Botto H, Palou J, Mazzei T: Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol. 2008, 54: 1164-1175. 10.1016\/j.eururo.2008.05.010.","journal-title":"Eur Urol"},{"key":"2090_CR3","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1093\/cid\/ciq257","volume":"52","author":"K Gupta","year":"2011","unstructured":"Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller RG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE: International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011, 52: e103-e120. 10.1093\/cid\/ciq257.","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 4","key":"2090_CR4","doi-asserted-by":"publisher","first-page":"S341","DOI":"10.1086\/382690","volume":"38","author":"DL Paterson","year":"2004","unstructured":"Paterson DL: \"Collateral damage\" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis. 2004, 38 (Suppl. 4): S341-S345.","journal-title":"Clin Infect Dis"},{"key":"2090_CR5","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/jac\/dkl432","volume":"58","author":"S Hillier","year":"2006","unstructured":"Hillier S, Bell J, Heginbothom M, Roberts Z, Dunstan F, Howard A, Mason B, Butler CC: When do general practitioners request urine specimens for microbiology analysis? The applicability of antibiotic resistance surveillance based on routinely collected data. J Antimicrob Chemother. 2006, 58: 1303-1306. 10.1093\/jac\/dkl432.","journal-title":"J Antimicrob Chemother"},{"key":"2090_CR6","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1086\/592250","volume":"47","author":"DA Talan","year":"2008","unstructured":"Talan DA, Krishnadasan A, Abrahamian FM, Stamm WE, Moran GJ: Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. Clin Infect Dis. 2008, 47: 1150-1158. 10.1086\/592250.","journal-title":"Clin Infect Dis"},{"key":"2090_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0732-8893(00)00135-8","volume":"37","author":"RN Jones","year":"2000","unstructured":"Jones RN, Biedenbach DJ, Johnson DM: Cefditoren activity against nearly 1000 non-fastidious bacterial isolates and the development of in vitro susceptibility test methods. Diagn Microbiol Infect Dis. 2000, 37: 143-146. 10.1016\/S0732-8893(00)00135-8.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2090_CR8","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.diagmicrobio.2009.01.017","volume":"64","author":"DJ Biedenbach","year":"2009","unstructured":"Biedenbach DJ, Jones RN: Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations. Diagn Microbiol Infect Dis. 2009, 64: 202-212. 10.1016\/j.diagmicrobio.2009.01.017.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2090_CR9","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1128\/AAC.01247-07","volume":"52","author":"D Sevillano","year":"2008","unstructured":"Sevillano D, Aguilar L, Alou L, Gim\u00e9nez MJ, Torrico M, Gonz\u00e1lez N, Cafini F, Rela\u00f1o MT, Coronel P, Prieto J: Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes\/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of cefditoren-pivoxil. Antimicrob Agents Chemother. 2008, 52: 1184-1186. 10.1128\/AAC.01247-07.","journal-title":"Antimicrob Agents Chemother"},{"key":"2090_CR10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijantimicag.2009.08.018","volume":"35","author":"I Katsarolis","year":"2010","unstructured":"Katsarolis I, Poulakou G, Athanasia S, Kourea-Kremastinou J, Lambri N, Karaiskos E, Panagopoulos P, Kontopidou FV, Voutsinas D, Koratzanis G, Kanellopoulou M, Adamis G, Vagiakou H, Perdikaki P, Giamarellou H, Kanellakopoulou K: Collaborative Study Group on Antibiotic Resistance in Community-acquired Urinary Tract Infections: Acute uncomplicated cystitis: from surveillance data to a rationale for empirical treatment. Int J Antimicrob Agents. 2010, 35: 62-67. 10.1016\/j.ijantimicag.2009.08.018.","journal-title":"Int J Antimicrob Agents"},{"key":"2090_CR11","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing","author":"Clinical and Laboratory Standards Institute","year":"2011","unstructured":"Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing. 2011, Wayne: CLSI, Twenty-First Informational Supplement, M100 - S21"},{"key":"2090_CR12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2165\/00003495-200262020-00006","volume":"62","author":"MJ Darkes","year":"2002","unstructured":"Darkes MJ, Plosker GL: Cefditoren pivoxil. Drugs. 2002, 62: 319-336. 10.2165\/00003495-200262020-00006.","journal-title":"Drugs"},{"key":"2090_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ijantimicag.2007.05.011","volume":"30","author":"KS Ko","year":"2007","unstructured":"Ko KS, Suh JY, Lee MY, Lee NY, Peck KR, Kwon KT, Jung DS, Song JH: In vitro activity of cefditoren against clinical isolates of Escherichia coli from a Korean hospital. Int J Antimicrob Agents. 2007, 30: 283-285. 10.1016\/j.ijantimicag.2007.05.011.","journal-title":"Int J Antimicrob Agents"},{"key":"2090_CR14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.diagmicrobio.2010.02.013","volume":"67","author":"O Cuevas","year":"2010","unstructured":"Cuevas O, Cercenado E, Gimeno M, Marin M, Coronel P, Bouza E: Comparative in vitro activity of cefditoren and other antimicrobials against Enterobacteriaceae causing community-acquired uncomplicated urinary tract infections in women: a Spanish nationwide multicenter study. Diagn Microbiol Infect Dis. 2010, 67: 251-260. 10.1016\/j.diagmicrobio.2010.02.013.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2090_CR15","unstructured":"European Committee on Antimicrobial Susceptibility Testing. available at: http:\/\/www.eucast.org\/eucast_disk_diffusion_test\/breakpoints\/"},{"key":"2090_CR16","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1128\/JCM.01797-08","volume":"47","author":"FC Tenover","year":"2009","unstructured":"Tenover FC, Emery SL, Spiegel CA, Bradford PA, Eells S, Bonomo RA EA, McGowan JE: Identification of plasmid-mediated AmpC beta-lactamases in Escherichia coli, Klebsiella spp. and Proteus species can potentially improve reporting of cephalosporin susceptibility testing results. J Clin Microbiol. 2009, 47: 294-299. 10.1128\/JCM.01797-08.","journal-title":"J Clin Microbiol"},{"key":"2090_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ijantimicag.2011.09.013","volume":"39","author":"G Kahlmeter","year":"2012","unstructured":"Kahlmeter G, Poulsen HO: Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO\u00b7SENS study revisited. Int J Antimicrob Agents. 2012, 39: 45-51. 10.1016\/j.ijantimicag.2011.09.013.","journal-title":"Int J Antimicrob Agents"},{"key":"2090_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/jac\/dkg028","volume":"51","author":"G Kahlmeter","year":"2003","unstructured":"Kahlmeter G, ECO.SENS: An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J Antimicrob Chemother. 2003, 51: 69-76. 10.1093\/jac\/dkg028.","journal-title":"J Antimicrob Chemother"},{"key":"2090_CR19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/jac\/dkm141","volume":"60","author":"S Hillier","year":"2007","unstructured":"Hillier S, Roberts Z, Dunstan F, Butler C, Howard A, Palmer S: Prior antibiotics and risk of antibiotic-resistant community-acquired urinary tract infection: a case\u2013control study. J Antimicrob Chemother. 2007, 60: 92-99. 10.1093\/jac\/dkm141.","journal-title":"J Antimicrob Chemother"},{"key":"2090_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1086\/422145","volume":"39","author":"TM Hooton","year":"2004","unstructured":"Hooton TM, Besser R, Foxman B, Fritsche TR, Nicolle LE: Acute uncomplicated cystitis in an era of increasing antibiotic resistance: a proposed approach to empirical therapy. Clin Infect Dis. 2004, 39: 75-80. 10.1086\/422145.","journal-title":"Clin Infect Dis"},{"key":"2090_CR21","unstructured":"Guidelines for the Diagnosis and Empirical Treatment of Infections. 2007, Athens: Hellenic Center for the Disease Control and Prevention, available at http:\/\/www.keelpno.gr\/Portals\/Infections_Book.pdf"},{"key":"2090_CR22","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.amjmed.2008.04.039","volume":"121","author":"L Johnson","year":"2008","unstructured":"Johnson L, Sabel A, Burman WJ, Everhart RM, Rome M, MacKenzie TD, Rozwadowski J, Mehler PS, Price CS: Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med. 2008, 121: 876-884. 10.1016\/j.amjmed.2008.04.039.","journal-title":"Am J Med"},{"key":"2090_CR23","unstructured":"Quinolone Restriction Formulary implemented by the Hellenic Drug Administration (EOF). available at http:\/\/eof1.eof.gr\/html\/law.html"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-12-228.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-12-228\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-12-228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-12-228.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T20:44:16Z","timestamp":1630529056000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-12-228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,25]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["2090"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-12-228","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,25]]},"assertion":[{"value":"10 March 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"228"}}